



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Table of Contents

- [Policy: Commercial](#)
- [Description](#)
- [Information Pertaining to All Policies](#)
- [Authorization Information](#)
- [Policy History](#)
- [Endnotes](#)
- [Coding Information](#)
- [References](#)

Policy Number: 557

BCBSA Reference Number: 2.04.29 (For Plan internal use only)

Related Policies

None

Policy¹

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Cologuard, a multitarget stool DNA test, is considered **MEDICALLY NECESSARY** as a colorectal cancer screening test for asymptomatic, average risk patients who meet all of the following criteria:

- Age 45 to 85 years, AND
- Asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), AND
- At average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn's Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).

All other DNA analysis of stool samples as a screening technique for colorectal cancer, in both patients with average to moderate risk and patients considered at high risk for colorectal cancer, is **INVESTIGATIONAL**.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is not required .
Commercial PPO and Indemnity	Prior authorization is not required .

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The above **medical necessity criteria MUST** be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
81528	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 dna markers (kras mutations, promoter methylation of ndrg4 and bmp3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result

The following HCPCS code is considered investigational for **Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

HCPCS Codes

HCPCS codes:	Code Description
G0327	Colorectal cancer screening; blood-based biomarker

DESCRIPTION

Colorectal Cancer

Several cellular genetic alterations have been associated with colorectal cancer (CRC). In the proposed multistep model of carcinogenesis, the tumor suppressor gene *p53* and the proto-oncogene *KRAS* are most frequently altered. Variants in adenomatous polyposis coli genes and epigenetic markers (eg, hypermethylation of specific genes) have also been detected. CRC is also associated with DNA replication errors in microsatellite sequences (termed microsatellite instability) in patients with Lynch syndrome (formerly known as hereditary nonpolyposis CRC) and in subgroups of patients with sporadic colon carcinoma. Tumor-associated gene variants and epigenetic markers can be detected in exfoliated intestinal cells in stool specimens. Because cancer cells are shed into the stool, tests have been developed to detect these genetic alterations in the DNA from shed CRC cells isolated from stool samples.

Summary

Detection of DNA abnormalities associated with colorectal cancer (CRC) in stool samples has been proposed as a screening test for CRC. This technology is another potential alternative to currently available screening approaches such as fecal occult blood testing, fecal immunochemical testing (FIT), and colonoscopy. The currently available stool DNA test combines FIT and DNA analysis and is referred to as FIT-DNA in this review, though other publications also use the terms stool DNA (sDNA)-FIT and multitarget stool DNA (mt-sDNA).

For individuals who are asymptomatic and at average risk of CRC who receive FIT-DNA, the evidence includes a number of small studies comparing FIT-DNA (in early stages of development) with colonoscopy, screening studies comparing the final version of the FIT-DNA (using colonoscopy as the reference standard), a systematic review of the screening studies, and modeling studies. Relevant

outcomes are overall survival and disease-specific survival. The screening studies have reported that FIT-DNA has higher sensitivity and lower specificity than FIT. There are no studies directly assessing health outcomes such as overall survival or disease-specific survival. The test characteristics of FIT-DNA show the potential of the test to be an effective CRC screening test, but there is uncertainty about other aspects of it. The screening interval for the test has not been firmly established nor is there evidence on the adherence of the test at a recommended screening interval. Effective screening for CRC requires a screening program with established screening intervals and appropriate follow-up for positive tests. Clinical utility of FIT-DNA is based on modeling studies. These studies have demonstrated that the diagnostic characteristics of FIT-DNA are consistent with decreases in CRC mortality that are in the range of other accepted modalities. FIT-DNA every 3 years is less effective than most other accepted screening strategies, while FIT-DNA every year is close to the efficacy of colonoscopy every 10 years. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Policy History

Date	Action
1/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
7/2021	Clarified coding information
1/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.
1/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2018	Annual policy review. New references added.
12/2016	Annual policy review. New references added.
1/2016	Clarified coding information.
10/2015	New medically necessary statement added for commercial plans. Effective 10/1/2015.
1/2015	CMS decision memo for screening for colorectal cancer - stool DNA testing (CAG-00440N) added. Clarified coding information. Effective 10/9/2014.
12/2014	Annual policy review. New references added.
2/2014	Annual policy review. New references added.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
7/2011	Reviewed - Medical Policy Group – Hematology and Oncology. No changes to policy statements.
3/21/2011	New policy describing ongoing non-coverage.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

- Exact Sciences Corporation. Cologuard Physician Brochure. Cologuard. <https://cdn2.hubspot.net/hubfs/377740/LBL-0260%20Rev%202%20FINAL.pdf>. Accessed October 4, 2021.

2. U.S. Food & Drug Administration (FDA). Premarket Approval (PMA) (P130017/S029). 2019; <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130017S029>. Accessed October 4, 2021.
3. U.S. Food & Drug Administration (FDA). Premarket Approval (PMA) (P130017/S042). 2020; <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P130017S042>. Accessed October 5, 2021.
4. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for Colorectal Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 202. AHRQ Publication No. 20-05271-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2021.
5. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*. Apr 03 2014; 370(14): 1287-97. PMID 24645800
6. Redwood DG, Asay ED, Blake ID, et al. Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. *Mayo Clin Proc*. Jan 2016; 91(1): 61-70. PMID 26520415
7. Cooper GS, Markowitz SD, Chen Z, et al. Performance of multitarget stool DNA testing in African American patients. *Cancer*. Oct 01 2018; 124(19): 3876-3880. PMID 30193399
8. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. *Gastroenterology*. Feb 2012; 142(2): 248-56; quiz e25-6. PMID 22062357
9. Ahlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. *Clin Gastroenterol Hepatol*. Mar 2012; 10(3): 272-7.e1. PMID 22019796
10. Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. *Clin Gastroenterol Hepatol*. Oct 2013; 11(10): 1313-8. PMID 23639600
11. Imperiale TF, Kisiel JB, Itzkowitz SH, et al. Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45-49 Year-Olds: A Cross-Sectional Study. *Cancer Prev Res (Phila)*. Apr 2021; 14(4): 489-496. PMID 33436397
12. Olson JE, Kirsch EJ, Edwards V DK, et al. Colorectal cancer outcomes after screening with the multi-target stool DNA assay: protocol for a large-scale, prospective cohort study (the Voyage study). *BMJ Open Gastroenterol*. 2020; 7(1): e000353. PMID 32128228
13. Berger BM, Kisiel JB, Imperiale TF, et al. Low Incidence of Aerodigestive Cancers in Patients With Negative Results From Colonoscopies, Regardless of Findings From Multitarget Stool DNA Tests. *Clin Gastroenterol Hepatol*. Apr 2020; 18(4): 864-871. PMID 31394289
14. Knudsen AB, Rutter CM, Peterse EFP, et al. Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force. *JAMA*. May 18 2021; 325(19): 1998-2011. PMID 34003219
15. D'Andrea E, Ahnen DJ, Sussman DA, et al. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality. *Cancer Med*. Jan 2020; 9(2): 824-836. PMID 31777197
16. Weiser E, Parks PD, Swartz RK, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening: Real-world data from a large cohort of older adults. *J Med Screen*. Mar 2021; 28(1): 18-24. PMID 32054393
17. Kisiel JB, Eckmann JD, Limburg PJ. Multitarget Stool DNA for Average Risk Colorectal Cancer Screening: Major Achievements and Future Directions. *Gastrointest Endosc Clin N Am*. Jul 2020; 30(3): 553-568. PMID 32439088
18. Barzi A, Lenz HJ, Quinn DI, et al. Comparative effectiveness of screening strategies for colorectal cancer. *Cancer*. May 01 2017; 123(9): 1516-1527. PMID 28117881
19. Johnson DH, Kisiel JB, Burger KN, et al. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. *Gastrointest Endosc*. Mar 2017; 85(3): 657-665.e1. PMID 27884518
20. Berger BM, Schroy PC, Dinh TA. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness. *Clin Colorectal Cancer*. Sep 2016; 15(3): e65-74. PMID 26792032
21. Blue Cross Blue Shield Association Technology Evaluation Center. Special Report: Fecal DNA Analysis for Colorectal Cancer Screening. TEC Assessment. 2014; Volume 29: Tab 8.
22. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 2.2021.

https://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Accessed October 4, 2021.

23. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. *Gastroenterology*. Jul 2017; 153(1): 307-323. PMID 28600072
24. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin*. Jul 2018; 68(4): 250-281. PMID 29846947
25. Davidson KW, Barry MJ, Mangione CM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. May 18 2021; 325(19): 1965-1977. PMID 34003218
26. Centers for Medicare and Medicaid Services (CMS). Decision Memo for Screening for Colorectal Cancer - Stool DNA Testing (CAG-00440N). 2014; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=277>. Accessed October 4, 2021.

Endnotes

¹ Based on Medicare Decision Memo for Screening for Colorectal Cancer - Stool DNA Testing (CAG-00440N)